# A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

> **NCT04825392** · PHASE1 · UNKNOWN · sponsor: **Taizhou Hanzhong biomedical co. LTD** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HX008

## Key facts

- **NCT ID:** NCT04825392
- **Lead sponsor:** Taizhou Hanzhong biomedical co. LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-05
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04825392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04825392, "A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04825392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*